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Abstract
In vertebrates, skeletal myogenesis involves the sequential activation of myogenic factors to lead ultimately to the
differentiation into slow and fast muscle fibers. How transcriptional co-regulators such as arginine methyltransferases
PRMT4/CARM1 and PRMT5 control myogenesis in vivo remains poorly understood. Loss-of-function experiments using
morpholinos against PRMT4/CARM1 and PRMT5 combined with in situ hybridization, quantitative polymerase chain
reaction, as well as immunohistochemistry indicate a positive, but differential, role of these enzymes during myogenesis in
vivo. While PRMT5 regulates myod, myf5 and myogenin expression and thereby slow and fast fiber formation, PRMT4/CARM1
regulates myogenin expression, fast fiber formation and does not affect slow fiber formation. However, our results show that
PRMT4/CARM1 is required for proper slow myosin heavy chain localization. Altogether, our results reveal a combinatorial
role of PRMT4/CARM1 and PRMT5 for proper myogenesis in zebrafish.
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Introduction
The proper control of gene expression is essential for normal
growth, development and differentiation. An early step in the
process of gene activation consists in modifying histones and
unraveling DNA sequences within promoter regions thereby
facilitating the recruitment of specific and general transcription
factors. Skeletal muscle differentiation involves cooperation
between the muscle regulatory factors (MRFs) Myod, Myf5,
Mrf4 and Myogenin [1], members of the Myocyte-enhancer
factors 2 (Mef2) family and chromatin remodelling or modifying
enzymes [2]. Numerous histone modifying enzymes have been
implicated in the regulation of myogenic genes in cell culture
including members of protein arginine methyltransferase (PRMT)-
families [2]. Of particular interest are two members of the PRMT
family, PRMT4/CARM1 (hereafter, called CARM1) and
PRMT5 as independent studies performed in cell culture or on
dissected skeletal tissues suggested that they are required for
myogenesis [3,4,5]. CARM1 methylates histone H3 on specific
arginine residues to regulate transcription [6,7], as well as non-
histone proteins such as the transcriptional co-activators CBP/
p300 [8,9,10,11]. Over the last few years, several studies have
shown that CARM1 acts as transcriptional co-activator in cell
proliferation and in a multitude of signaling pathways [12,13].
Similarly, PRMT5 methylates histones H3 and H4 as well as non-
histone proteins but has been shown to regulate negatively cell
proliferation [13,14]. These data suggest that CARM1 and
PRMT5 play a central role in muscle differentiation in cell culture
and most likely in vivo. However, the mechanisms by which these
enzymes control myogenesis have not been addressed yet. Indeed,
no other report has addressed the precise role(s) of CARM1 and
PRMT5 in vivo during development and particularly in myogen-
esis. To gain insights into their function in vivo, we turned to
zebrafish to analyze their shared and divergent roles in
myogenesis.
In zebrafish, cells are committed to the myogenic fate through
the activation and the cooperation of MRFs and Mef2 proteins
[15]. Then, committed myoblasts differentiate into muscles fibers
with distinct genes expression profiles and contraction speeds, the
so-called slow- and fast-twitch fibers. In the zebrafish embryo,
progenitors of the slow and fast muscle fibers can be identified on
the basis of their morphology, their position within the segmental
plate before somites formation and the expression of a specific set
of genes [16]. It has been shown recently that myf5 and myod, but
not myogenin, are required and cooperate to drive myoblast
progenitor (also called adaxial cells) commitment to the slow fiber
type [17] whereas fast fiber differentiation occurs during the
migration of slow fibers and relies on the expression of myf5 and
myod but also of myogenin [17,18]. Here, we investigated the
involvement of CARM1 and PRMT5 in myogenesis in zebrafish
embryos. We found that both CARM1 and PRMT5 control
myogenin expression whereas PRMT5, controls the expression of
the early genes myod and myf5. Accordingly, we demonstrated that
these enzymes affect proliferation negatively and act in myogenic
differentiation. We subsequently showed that both PRMT5 and
CARM1 control fast muscle fiber formation whereas PRMT5
triggers slow muscle fiber formation. Finally, we found that if a
decrease of CARM1 expression was not affecting the initial step of
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Hence, our results indicate that PRMT5 and CARM1 play a
combinatorial role in zebrafish myogenesis.
Results and Discussion
CARM1 and PRMT5 are dynamically expressed during
development
Expression pattern of CARM1 and PRMT5 during zebrafish
development was first analyzed by in situ hybridization. We found
that both CARM1 and PRMT5 were robustly expressed at 2-cell
stage indicating that they are maternal genes (Figure 1A). At
gastrulation, CARM1 was strongly expressed in the dorsal shield,
whereas PRMT5 was weakly present in this domain. Of note, both
CARM1 and PRMT5 were expressed within the somites during
early somitogenesis and enriched in the presomitic mesoderm
(PSM, Figure 1A–1C, asterisk), a structure that will give rise to the
somites [19]. That both genes are expressed in the PSM suggests
that CARM1 and PRMT5 may contribute to the maintenance of
somite progenitors in this area.
Interestingly, PRMT5 and CARM1 were expressed in the
somites from 6- to 18-somite stage during segmentation
(Figure 1A and 1B). Around 24 hours post fertilization (24 hpf),
somitogenesis is completed and PRMT5 was preferentially
expressed in the posterior trunk and in tail somites with a weaker
expression in anterior trunk somites, whereas CARM1 was
expressed all along the axis with a strong expression in the
anterior neural structures (Figure 1A). To gain further insight into
the expression of CARM1 and PRMT5 in the somites, we analyzed
them in flat-mounted embryos and in the corresponding cross
sections at 14-somite stage (14 ss). PRMT5 expression was not
detected in the adaxial progenitor cells and was enriched in the
medial part of the somite, whereas CARM1 was ubiquitously
expressed in the somite (Figure 1C and 1D). That PRMT5 and
CARM1 are expressed in different parts of the somites suggests that
they may act differentially on myogenesis.
CARM1 and PRMT5 are essential for proper myogenesis
To examine the involvement of CARM1 and PRMT5 in
myogenesis, we interfered with their translation using antisense
morpholinos (Mo). Expression of endogenous CARM1 and
PRMT5 was strongly reduced after injection of their respective
morpholino, as confirmed by western blot (Figure 2A and 2B).
Phenotypes of the morphants on the somites were analyzed at 14–
16 ss and 24 hpf under polarized light. PRMT5 loss of function
gave rise to embryos with long and flat somites, whereas CARM1
morphants showed smaller and rounder somites (Figure 2C and
Table 1). Of note, the same morphant phenotypes were obtained
after injection of another specific morpholino against CARM1 or
PRMT5 (data not shown). These phenotypes were rescued at both
stages when CARM1 or PRMT5 mRNAs were co-injected with
their cognate morpholino (Table 1, Figure 2C, panels MoP5+P5,
MOC1+C1 and Figure 2D, panels j and k). Furthermore, the
phenotypes observed at 24 hpf were dependent on the dose of
morpholinos injected (Table 1 and Figure 2D). Altogether, these
data demonstrate the specificity of CARM1 and PRMT5
morpholinos and indicate that both CARM1 and PRMT5 are
required for proper axis formation. The round shape of the
somites at 14 ss in CARM1 morphant suggests that CARM1 could
be involved in the elongation of muscle progenitor cells that are
Figure 1. PRMT5 and CARM1 are differentially expressed during zebrafish embryogenesis. (A–D) CARM1 and PRMT5 in situ hybridization at
the indicated stages. (A) Animal view (av), lateral view (lv, dorsal to right for 6 hpf, anterior to left for 24 hpf) and dorsal views (dv, anterior to top)o f
whole-mount zebrafish in situ hybridization. (B) Dorsal view (anterior to top) of CARM1 and PRMT5 expression during somitogenesis. (C) Dorsal flat-
mounts of 14 ss embryos stained for CARM1 and PRMT5. A magnified region is shown on the right. (D) Transverse sections (30 mm) of the magnified
region in (C) showing undetectable PRMT5 expression in adaxial cells (arrow), whereas CARM1 is ubiquitously expressed in the somite. *, Presomitic
Mesoderm (PSM); ss, somite stage.
doi:10.1371/journal.pone.0025427.g001
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involved in somite boundary formation [20].
PRMT5 and CARM1 regulate differentially myogenic
factor expression
To further characterize the impact of CARM1- and PRMT5-
loss of function, we first focused on their putative role on
mesodermal markers expression at gastrulation. We found that
although CARM1 and PRMT5 were expressed in the shield during
gastrulation (Figure 1A), their knock down did not affect the
expression of the organizer gene goosecoid/gsc (data not shown), or
of the mesodermal gene spadetail/spt/tbx16 (Figure S1A), a key
regulator of myod expression [21,22]. Hence, CARM1 and
PRMT5 are not required in early mesoderm specification, from
where the somites arise.
We then analyzed the impact of CARM1- or PRMT5- knock
down on the expression of key regulators of zebrafish myogenesis,
Figure 2. PRMT5 and CARM1 morphants exhibit distinct and specific phenotypes. (A, B) One-cell embryos were injected with 6 ng of
either a control morpholino (MoCt), or a morpholino against PRMT5 (MoP5) or CARM1 (MoC1). Embryos were collected at 14 ss and were processed
for immunoblotting to detect (A) PRMT5 and (B) CARM1 expression. Tubulin was used as a loading control. (C) Lateral (anterior to left) and dorsal view
(anterior to top) of 14–16 ss zebrafish embryos injected with the indicated morpholino. Rescue experiments by injection of the cognate mRNA are
shown to the right (MoP5+P5, MoC1+C1). Schematic representations of each somite are shown below the corresponding dorsal view. Mo,
morpholino. (D) Phenotypes of 24 hpf embryos injected with increasing doses (3-6-12 ng) of Control (MoC, a–c), PRMT5 (MoP5, d–f) or CARM1 (MoC1,
g–i) morpholinos or 6 ng of morpholino against PRMT5 or CARM1 co-injected with their corresponding mRNA (MoP5+P5, j and MoC1+C1, k) for
rescue experiment. Embryos were visualized at 24 hpf. Lateral view, anterior to the left.
doi:10.1371/journal.pone.0025427.g002
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and at 18 ss (Figure 3). Strikingly, we observed that at 14 ss
PRMT5 Mo diminished the expression of myod, whereas CARM1
knock down had no effect on the expression of this gene (Figure
S1B). In addition, PRMT5 morphants exhibited a significant
reduction of myf5, myogenin and mef2c expression (Figure 3 and
Figure S2). Myf5 and mef2c expression were affected all along the
axis, whereas myogenin expression was mostly diminished in the
posterior somites, that host the fast muscle precursors (Figure S2B,
arrow), and faintly decreased in the medial part of the somite. On
other hand, CARM1 depletion down-regulated the expression of
myogenin and mef2c (Figure 3 and Figure S2B) and lead to a slight
increase of myf5 expression in the most medial part of anterior
somite (Figure 3A asterisk, and Figure S2A asterisk). To confirm
these results, we analyzed the expression of these genes by
quantitative PCR on Mo-injected 14 ss (Figure S2B) and 18 ss
(Figure 3B) embryos. Consistent with the above results, PRMT5
knock down induced a significant decrease of myf5, myogenin and
mef2c expression levels whereas CARM1 knock down lead to a
decrease of myogenin and mef2c levels and to an increase of myf5
expression at 18 ss (Figure 3B and Figure S2B). Of note, PRMT5
or CARM1 loss did not appear to affect the expression of each
other (Figure S3), suggesting that the phenotypes observed in each
morphant were not due to the deregulation of the other enzyme.
Accordingly, decrease of myogenin expression by either PRMT5 or
CARM1 Mo was specifically and strictly rescued by the cognate
mRNA and not by the other one (Figure S4). Furthermore, that
myogenic gene expression was affected in a similar way in the
morphants at 18 ss as at 14 ss further supports that the effects
observed are specific and excludes any developmental delay
(Figure 3 and Figure S2).
It has been shown previously that PRMT5 was required for the
activation of myogenin in cell culture and in muscle tissues [4,5].
Our study reveals that PRMT5 controls myogenesis at an earlier
step by regulating myod and myf5 expression. Hence, it is likely that
PRMT5 controls myogenesis via a two-tiers mechanism: first, our
study shows that it up-regulates myod (Figure 3 and Figure S1B)
and myf5 expression (Figure 3 and Figure S2), second, as
demonstrated in cell culture, it also cooperates with Myod or
Myf5 to activate myogenin expression [5]. As PRMT5 morphant did
not show any defect in spadetail expression (Figure S1A), a gene
that controls the onset of myod expression [21,22], we propose that
PRMT5 may activate directly myod and myf5 expression by being
recruited onto their promoters as it has been demonstrated for
myogenin in cell-based assays [4]. However, we cannot rule out that
PRMT5 could also affect their expression indirectly or post-
transcriptionnally via its enzymatic activity.
Table 1. Morphological defects of somites in zebrafish
embryos injected with morpholinos against CARM1 or PRMT5.
Percentage of embryos for
each class of phenotype
Number of embryos
injected (n) Wild type Low Mild Severe
14 ss
MoCt (465) 100 0 0 0
MoC1 (355) 35 65* 00
MoP5 (431) 0.07 0 99.93# 0
MoC1+C1 (370) 87.5 12.5* 00
MoP5+P5 (295) 90 0 10# 0
24 hpf
MoCt (111) 100 0 0 0
MoC1a (142) 28.5 71.5 0 0
MoC1b (116) 0 22.4 77.6 0
MoC1c (129) 0 29.5 24 46.5**
MoCt (136) 100 0 0 0
MoP5a (126) 0.02 0 99.98 0
MoP5b (119) 0 0 45.3 54.7**
MoP5c (96) 0 0 19.8 80.2**
14 ss: embryos were injected at the one cell stage with 6 ng of morpholinos
against CARM1 (MoC1), PRMT5 (MoP5) or control morpholinos (MoCt). Rescue
experiments were performed by co-injecting MoC1 or MoP5 with the mRNA
coding for CARM1 (MoC1+C1) or PRMT5 (MoP5+P5), respectively.
24 hpf: Morpholino doses used for 24 hpf phenotype analysis were the
following: 3 ng (a), 6 ng (b) and 12 ng (c). Percentages of embryos exhibiting
the various phenotypes at 14 ss and 24 hpf are shown.
*Round, smaller somites;
#Flat, longer somites;
**Shorter axis.
doi:10.1371/journal.pone.0025427.t001
Figure 3. PRMT5 and CARM1 regulate myogenic factor
expression. Expression of myod, myf5, myogenin and mef2c at 18 ss
in embryos injected with the indicated Mo by (A) whole-mount in situ
hybridization (lateral view, anterior to left; a dorsal view, anterior to top,
is shown on the right; *, anterior expression of myf5 in CARM1
morphant) or (B) real time PCR. Error bars represent standard deviations.
*, P,0.01 statistically significant; **, P,0.001, very statistically
significant; ***, P,0.0001, extremely statistically significant; ns, not
statistically significant, using a t-test.
doi:10.1371/journal.pone.0025427.g003
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specifically control the down-regulation of myf5 expression in the
mature somite (Figure 3). It has been shown that CARM1
methylates RNA-binding protein HuD thereby affecting the
stability of HuD target mRNAs [23] and that CARM1 can act
either positively or negatively on mRNA stability of a certain
number of c-Fos target genes [24]. One can speculate that
CARM1 could regulate myf5 expression post-transcriptionnally in
a similar way. Our data showing that CARM1 regulates myogenin
expression in vivo are in agreement with the original report showing
that CARM1 activates myogenin expression in cell-based studies [3].
However, a recent study has reported a role of co-activator of
Myogenin-dependent transcription for CARM1 but without
affecting myogenin expression [5]. Of note, this study was performed
in Myod-differentiated fibroblasts and C2C12 myoblasts. Here,
our data indicate that in a whole organism, CARM1 regulates
myf5, myogenin and mef2c expression. Hence, PRMT5 and CARM1
are not only co-activators of Myod- and Myogenin-dependent
transcription respectively, but they also control the expression of
these myogenic factors.
PRMT5 and CARM1 control slow and fast myogenesis
differentially
To address whether PRMT5 and CARM1 could affect slow
and/or fast myogenesis we analyzed the expression of slow myosin
heavy chain 1 (smyhc1), a slow fiber specific gene and of fast myosin
light chain (mlc2f), a fast fiber specific gene in PRMT5- and
CARM1-depleted embryos as compared to control embryos. In
PRMT5 morphants, mlc2f was dramatically reduced as compared
to control morphants (Figure 4A) and smyhc1 expression was
completely lost in the lateral part of the somite (Figure 4C, arrow).
CARM1 knock down restrained smyhc1 expression medially
(Figure 4C, red arrowhead) and mlc2f expression almost disap-
peared (Figure 4A). These data were confirmed by immunohis-
tochemistry against fiber-specific myosin isoforms at two different
stages (14 ss, Figure 4B and 4D; 18 ss, Figure S5). PRMT5 knock
down lead to a strong decrease in slow muscle fiber formation and
suppressed fast muscle fibers at both stages (Figure 4B and 4D and
Figure S5).
Interestingly, PRMT5 was not detected in adaxial cells
(Figure 1D) and our results suggest that this enzyme can control
slow muscle fiber formation. Several possibilities can be proposed
to explain this apparent paradox. First, even though PRMT5 was
not detected in adaxial cells in our in situ hybridization
experiments, it could be nevertheless very weakly expressed and
thus active in these cells. Another possibility is that PRMT5 could
act non-cell autonomously in adaxial cells. Finally, PRMT5 would
not be required for the activation of smyhc1 expression but for its
maintenance. Indeed, if expression of smyhc1 was weakly affected
by PRMT5 knock down, its protein level was barely detectable in
the same condition (Figure 4C and 4D). These results suggest that
PRMT5 controls smyhc1 expression post-transcriptionally. We can
speculate that, either PRMT5 is specifically required for smyhc1
translation, or PRMT5 is somehow involved in SMYHC1
stability. Interestingly, it has been shown recently that PRMT5
was required for the expression of myogenic microRNAs [25].
Hence, one possibility is that PRMT5 could control smyhc1
translation by affecting the expression of these miRNAs. Further
studies would be needed to elucidate whether and how PRMT5
controls SMYHC1 protein synthesis and/or stability.
Figure 4. CARM1 and PRMT5 differentially control slow and fast myogenesis. (A, C) Dorsal flat-mounted 14 ss embryos (anterior to top)
injected with the indicated Mo were analyzed by whole-mount in situ hybridization for (A) mlc2f and (C) smyhc1 or (B, D) immunohistochemistry for
(B) fast fibers, (D) slow fibers. In (C) a magnification of the area indicated by the black line is shown to the right of each panel. Arrow or white
arrowhead, lateral expression; red arrowhead, medial expression; red bar, length of one somite. (B, D) Z-stack sections of the most anterior somites
are shown.
doi:10.1371/journal.pone.0025427.g004
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and a restriction of the slow fiber marker to the midline (Figure 4B
and 4D and Figure S5). This pattern is reminiscent of embryos
mutated in M- or N- Cadherin that control slow muscle cell migration
in the developing zebrafish myotome [26] and is in line with
CARM1 morphant phenotype that generates round somites. We
then went on to analyze slow fiber proper localization in CARM1
knock down. We found that slow muscle fiber localization was
affected in CARM1 morphants (Figure 4D and Figure 5). More
investigations will be needed to analyzewhetherCARM1is involved
in slow muscle fiber localization and regulates cadherin expression.
Altogether, these results clearly show that PRMT5 is essential for
slow and fast myogenesis, whereas CARM1 only controls fast fiber
formation and is required for proper slow muscle fiber localization.
Having shown that CARM1 and PRMT5 control muscle cell
fiber formation, we analyzed whether they also regulate cell
proliferation in the somite as CARM1 and PRMT5 have been
shown in cell culture to regulate cell proliferation, either positively
[27] or negatively [14], respectively. Surprisingly, we found that at
14 ss, loss of either CARM1 or PRMT5 increased significantly the
number of mitotic cells within the somite (Figure 6). This effect was
rescued when CARM1 or PRMT5 mRNAs were co-injected with
their cognate morpholino (Figure 6, MoP5+P5, MoC1+C1).
Hence, these data indicate that both enzymes trigger cell cycle
arrest and myogenic differentiation during development. We
propose that CARM1 and PRMT5 could control the timing of
muscle fiber formation by regulating the switch between
proliferation and cell cycle exit.
Figure 6. CARM1 and PRMT5 control cell cycle arrest during development. (A) Dorsal flat-mounted of 14 ss embryos (anterior top) injected
with the indicated Mo or co-injected with the corresponding mRNA for rescue experiments were analyzed by immunohistochemistry for mitotic cells
with an anti phospho-H3 (Ser10) antibody. (B) Representation of the number of mitotic cells per somite. Error bars represent standard deviations.
***, P,0.0001 extremely statistically significant; ns, not statistically significant, using a t-test.
doi:10.1371/journal.pone.0025427.g006
Figure 5. CARM1 controls slow fiber localization. (A, B) One-cell stage embryos were injected with a CARM1 morpholino (MoC1) or a control
morpholino (MoCt) and were analyzed at 24 hpf by whole-mount immunohistochemistry for slow fibers. (A) Lateral views, anterior to the left of 3D
confocal reconstructions projected over four somites, (A9) single confocal scans at the dorsoventral level of the notochord and (A0) corresponding
cross-section views. (B) Rostral cross-sections (50 mm) of 22 ss embryos injected with the indicated morpholino.
doi:10.1371/journal.pone.0025427.g005
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PRMT5 to control MRF and mef2c expression as well as slow and
fast myogenesis in zebrafish. Recent studies have emphasized the
role of methylation of non histone proteins such as transcriptional
co-regulators, transcription elongation factors and RNA binding
proteins by CARM1 and PRMT5 [28]. It is tempting to speculate
that through their enzymatic activity on specific substrates, these
enzymes could regulate the transcriptional activity, protein-protein
interactions, protein stability and/or protein sub-cellular localiza-
tion of key factors involved in myogenesis. It was found that
CARM1 interacts with Myogenin and Mef2D, whereas PRMT5
can bind Myod, Myogenin and Mef2D in vitro [5]. To further
elucidate how these enzymes control myogenesis it would be of
particular interest to analyze whether they methylate some
myogenic factors. Indeed, methylation could modulate the
interactions between MRFs or Mef2 and specific partner(s), notably
transcriptional co-activators/mediators or ATP-dependent chro-
matin remodeling enzymes to activate transcription on target genes.
In summary, this study demonstrates that CARM1 and
PRMT5, two transcriptional co-regulators that have been shown
respectively to act positively and negatively on proliferation in cell-
based assays, are both inhibiting proliferation and are required for
myogenic differentiation in a whole organism. However, they play
distinct roles in myogenesis: PRMT5 regulates slow and fast fiber
formation by controlling early myogenic genes (myod and myf5)a s
well as myogenin, whereas CARM1 is required for fast fiber
formation by regulating myogenin expression. Interestingly, our data
also show that if CARM1 has no impact on slow fiber formation it
is required for their proper localization.
Methods
Ethics Statement
All embryos were handled according to relevant national and
international guidelines. French Ministery of Agriculture approved
the protocols in this study, with approval ID: B-31-555-10.
Embryos, synthetic mRNAs, morpholinos and injections
Zebrafish were raised according to standard procedures [29].
Injections were performed at one-cell stage with 250 pg of CARM1
RNA [6], 250 pg of PRMT5 RNA [30] and 6 ng of the indicated
morpholinos (Gene-tools). Morpholino sequences were: PRMT5
59-GACGCCATCGTTAGGAGACGAGATG-39; CARM1 59-
GAGAACACGGACACCGC CATCTTCG-39; Control 59-
CCTCTTACCTCAG TTACAATTTATA-39.
Whole-mount in situ hybridization, immunostaining and
image acquisition
Whole-mount in situ hybridization and antibody staining were
performed according to standard protocols. In situ hybridization
was performed with digoxigenin-labeled probes transcribed from
plasmids containing cDNA for spt [31], myod and myogenin [22],
myf5 [32], mef2c [33], smyhc1 [34] and mlc2f [35]. zCARM1 and
zPRMT5 anti-sense probes were obtained by sub-cloning their
corresponding ESTs BC078292 and BC095362 respectively
(Open Biosystems, Huntsville, AL, US), into pBluescript KS
(Stratagene, La Jolla, CA, US) using EcoRI/HindII (zCARM1)
and XmaI/HindIII (zPRMT5) and were transcribed with T3
polymerase. For cross-sections, embryos were embedded in 3%
Low Melting Agar after whole-mount in situ hybridization and
30 mm sections were performed using a Leica vibratome (VT
1000S). For immunohistochemistry, the following antibodies were
used: F310 fast Myosin Light Chain (DSHB), F59 slow Myosin
Heavy Chain (DSHB) and phospho-Histone H3 (ser10) (Upstate,
Greenville, SC, US) with appropriate Alexa Fluor-conjugated
secondary antibodies (Molecular Probes, Eugene, OR, US). Nuclei
were stained with TO-PRO3 (Molecular Probes, Eugene, OR,
US) according to the manufacturer’s protocol. Embryos were
dissected, flat-mounted in glycerol or mounted in Mowiol and
images were recorded on a microscope (NIKON Eclipse 80i) using
a2 0 6 Plan Apo na 0.5 or a 406 plan Apo na 1 with the NIS-
element AR 2.30 software; or on a confocal microscope (TCS SP5,
Leica Microsystems) with a 206Plan Apo na 0.7 objective (zoom
64) using the scanner resonant mode. Confocal images are stacks
of the anterior somites of 14 or 18 ss embryos as stated in figure
legends. For whole embryos, imaging was performed using a
stereomicroscope (Leica MZ FL III) with the ACT-1C software.
RNA extraction and reverse transcription
Total RNAs were extracted from 25 embryos at 14 ss or 18 ss as
stated in figure legends with the RNeasy mini kit (Qiagen, Valencia,
CA, US), eluted in RNAse free water and reverse-transcribed with
the Superscript II Reverse Transcriptase (Invitrogen, Carlsbad, CA,
US) according to the supplier’s instructions.
Quantitative PCR
Q-PCR analyzes were performed on an i-Cycler device (Biorad,
Hercules, CA,US) with the SYBRgreen JumpStartTaqReady mix
(Sigma Aldrich, St. Louis, MO, US), according to the manufactur-
er’s instructions. All experiments included a standard curve.
Samples were analyzed in triplicates and the mean and standard
deviation were calculated. Samples were normalized to the number
of EF1 mRNA copies. Primer sequences were the following: myod fw
59- GCCCAAAGTGGAGATTCTGA-39, rev 59- GCCCATAA-
AATCCATCATGC-39; myf5 fw 59-GAGAGCATGGTTGACT-
GCAA-39, rev 59-GAATCACTTCCGGTTGGAGA-39; myogenin
fw 59-AAACCATCTCCATCGTCCAG-39; rev 59-GGGTTCAT-
CAATGT GCTCCT-39; Mef2c fw 59-GGTCTCTCCAGGGAA-
CATGA-39, rev 59-GCCCATCACTT CTCCAGGTA-39; EF1-
alpha fw 59-GATGCACCACGAGTCTCTGA-39, rev 59-TGAT-
GACCT GAGCGTTGAAG-39.
Western Blotting
Whole cell extracts from 25 zebrafish embryos were classically
prepared in 50 ml Laemmli sample buffer. 10 ml of each sample (5
embryos) were loaded per lane and subjected to SDS-PAGE. The
following commercial antibodies were used: anti-CARM1 (US
Biologicals, P9004-20C), anti-PRMT5 (Upstate, 07-405), anti
alpha-Tubulin (Sigma, T9026), anti-Rabbit IgG HRP conjugate
(Promega, W4011) and anti-Mouse IgG HRP conjugate (Pro-
mega, W4021).
Supporting Information
Figure S1 PRMT5 and CARM1 regulate myogenic factor
expression. (A–B) In situ hybridization of embryos with the
indicated mRNA probe and injected with the indicated Mo (A) at
the shield stage or (B) at 14 ss. (A) Animal view (dorsal to right). (B)
Dorsal flat-mounted embryos stained for myod with a magnified
region to the right.
(TIF)
Figure S2 PRMT5 and CARM1 regulate specifically
myogenic factors expression at 14-somite stage (14 ss).
Whole-mount in situ hybridization of embryos injected at one-cell
stage with the indicated morpholino (Mo). Experimentrs were
done twice with n=20 for each condition. Embryos were collected
at 14 ss and were analyzed for myogenic factors expression by (A)
CARM1 and PRMT5 Control Myogenesis in Zebrafish
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e25427in situ hybridization, lateral view, anterior to the left or by (B) real
time PCR with standard deviations relative to a control
morpholino. Q-PCR procedures are detailed in the methods
section. (A) Asterisk, anterior expression of myf5 in CARM1
morphant; arrow, down regulation of myogenin expression in the
posterior somites in PRMT5 morphant. (B) Error bars represent
standard deviations. *, P,0.01; **, P,0.001; ***, P,0.0001; ns,
not statistically significant.
(TIF)
Figure S3 Knock down of CARM1 or PRMT5 does not
affect their mutual expression. One-cell stage embryos
injected with either a control morpholino (MoCt), or a morpholino
against PRMT5 (MoP5) or against CARM1 (MoC1) (left panels).
Mos were co-injected with either PRMT5 mRNA (MoP5+P5) or
CARM1 (MoC1+C1) (right panels). Embryos were collected at 14-
somite stage and analyzed for CARM1 and PRMT5 expression by
in situ hybridization. Note that PRMT5 expression is strongly
enhanced in MoP5-injected embryos (white asterisk), which can be
rescued by the co-expression of PRMT5 mRNA (black asterisk).
(TIF)
Figure S4 PRMT5 and CARM1 mRNAs rescue specifi-
cally myogenin expression affected by their cognate
morpholino(*). One-cell stage embryos were injected with
either a morpholino control (MoCt), or a morpholino against
PRMT5 (MoP5) or CARM1 (MoC1), alone or in combination
with either PRMT5 or CARM1 mRNA. Embryos were collected at
14-somite stage and were analyzed for myogenin expression by in situ
hybridization. Experiments were done twice (n=22 for each
condition).
(TIF)
Figure S5 CARM1 (C1) and PRMT5 (P5) control myo-
genesis differentially. (A,B) One-cell stage embryos were
injected with the indicated morpholino (Mo) or a control Mo
(MoCt) and were analyzed by whole-mount immunohistochemis-
try for (A) slow fibers and (B) fast fibers at 18-somite stage. Lateral
views, anterior to the left. Both slow and fast fiber formation
require PRMT5 (n=12). CARM1 is necessary for fast fiber
specification but does not affect slow fiber specification (n=15).
Antibodies used were: F310 fast Myosin Light Chain (DSHB), F59
slow Myosin Heavy Chain (DSHB) and appropriate Alexa Fluor-
conjugated secondary antibodies (Molecular Probes, Eugene, OR,
US). Nuclei were stained with TO-PRO3 (Molecular Probes,
Eugene, OR, US) according to the manufacturer’s protocol.
(TIF)
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